Spero Therapeutics Inc (SPRO NASDAQ) stock market data APIs
$2.3567
-0.04(-1.7%)
as of October 30, 2025
Try our APIs with
free plan!
Spero Therapeutics Inc Financial Data Overview
Price chart is built with
Anychart
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Prev. Close
2.3567
Open
2.3168
High
2.4246
Low
2.322
52 wk Range
0.5052-3.22
Market Cap
133 M
Shares Outstanding
56 275 K
Revenue
48 576 K
EPS
-0.03
Beta
1.465
* We provide hundreds of fields of fundamental data, including EBITDA, P/E ratio, PEG ratio, trailing P/E, shareholders, insider transactions, technical metrics, dividends, splits, earnings, and more. Check out our Fundamental Data API.
ETFs with Spero Therapeutics Inc (top by weight)
Ticker
100-day Price Change
Weight
* We provide detailed information about ETF constituents through our Fundamentals API for ETFs. Read the documentation to learn more.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Spero Therapeutics Inc data using free add-ons & libraries
Get Spero Therapeutics Inc Fundamental Data
Spero Therapeutics Inc Fundamental data includes:
- Net Revenue: 48 576 K
- EBITDA: -56 357 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-08-12
- EPS/Forecast: -0.57
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Spero Therapeutics Inc News
New
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatment1Data will be shared with...
PIVOT-PO Phase 3 Data Show Tebipenem HBr’s Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs)
Spero Therapeutics, Inc. Data presented at IDWeek 2025 after study stopped early for efficacy Primary endpoint met, demonstrating non-inferiority of oral tebipenem HBr compared to intravenous treatme...
Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease
Bayer AG’s BAYRY wholly owned, independently operated subsidiary BlueRock Therapeutics LP announced positive 36-month data from an early-stage study of bemdaneprocel, an investigational cell therapy...
October 2025's Promising Penny Stocks To Consider
As U.S. stock indexes continue to rise, even amid a government shutdown, investors are keeping a close eye on market dynamics and economic indicators. In this context, penny stocks—despite the somew...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
